| Objective：Through to the sorafenib treatment of metastatic renal cell carcinoma(mRCC) assessment of the effect of clinical cases and adverse reactions were observedin28patients, of sorafenib in the treatment of metastatic renal cell carcinoma (mRCC)clinical benefit patients, patients in the clinical treatment of management strategies.Methods：Twenty-eight patients with metastatic renal cell carcinoma were enrolledfrom September2009to December2011.All of the patients were given sorafenib at adosage of400mg two times a day orally, continuous administration, until tumorprogression or intolerable toxicity,2patients because of economic reasons to stop drug didnot finish the treatment. The treatment lasted from3to20months. Objective response rate(ORR), progressive free survival (PFS) and overall survival (OS) were evaluated, andadverse events were also observed.Results：Two cases because of economic reasons withdraw from the treatment,26patients were evaluable for efficacy, no CR cases, PR5cases, SD18cases, PD3cases,including2deaths. The median progression-free survival and overall survival for shortfollow-up could not be evaluated. The most common adverse events associated withtreatment of diarrhea, rash, desquamation, fatigue, hand-foot skin reaction, alopecia,nausea, vomiting, itching, hypertension and loss of appetite. By supporting treatment anddrug reduction, more adverse reactions can be controlled.Conclusion：Sorafenib therapy in the treatment of advanced metastatic renal cellcarcinoma (mRCC) has significant curative effect and higher rates of disease control.Treatment related adverse reaction can be controlled. Subjects can be tolerated andsecurity is good, but the long-term efficacy and safety evaluation need longer time and larger samples follow-up. |
PDF Full Text Request